ACTC Jumps 10%
ACTC jumped 10% in afternoon trading after a report that the company has reversed blindness in rats using stem cells.
"ACT has previously reported it used human embryonic stem cells to make retinal cells. They have reversed blindness in rats."
Please consult a registered investment adviser before making any investment decision.
posted by Stock Forums @ 10:45 AM
1 comments
1 Comments:
$UVFT kills Swine Flu, FDA approved products!!!! $$
UVFT (UV Flu Technologies Inc.) has just released an FDA Approved medical device that kills the SWINE FLU!! UV Flu Technologies has just obtained all assets of "AmAirPure, Inc". UV 400 ViraGuard(TM) is the product and it kills "99.2% of harmful airborne microbes" INCLUDING the swine flu!
UV Flu Technologies Inc. (UVFT) develops highly innovative germicidal air purification technology that disinfects indoor air by deactivating allergens and killing airborne pathogens including bacteria, viruses and mold. The Company’s flagship product, the UV 400 ViraGuard(TM), utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtering to trap and destroy harmful microbes. Extensive independent testing by EPA and FDA certified laboratories confirms the proprietary system captures and kills airborne bacteria including Bacillus subtilis, Pseudomonas aeruginosa, Staphylococcus aurous, Klebsiella pneumonia and viruses including Influenza A and H1N1 at rates exceeding 99.2% on a first-pass basis.
Breathe Easier with UVFT
the H1N1 pandemic is highlighting the growing need for technologies, products and services that protect against the threat of airborne illness. With its leading edge germicidal air purification technology, proven ability to deactivate harmful viruses, bacteria, mold and allergens with over 99% effectiveness and seasoned management team, UV Flu Technologies is in position to capture a significant share of the thriving market for indoor air quality product.
Sources www.pennystocklive.com http://www.uvflutech.com/
Post a Comment
<< Home